Location: Remote, anywhere in Europe. Ability to travel to Paris would be beneficial.
Commitment: 2 to 3 days per week
Start: ASAP
Duration: Initial contract through to end September, with potential to extend or convert

We are supporting a European pharmaceutical organisation with an urgent requirement for an experienced HEOR professional to step into a high visibility oncology asset at ex US level.

This role will take ownership of the company’s first Joint Clinical Assessment, JCA, submission. As such, it is both strategically important and operationally critical. The successful candidate will lead coordination of the JCA dossier, ensuring alignment across internal stakeholders and external vendors, while maintaining compliance with EU27 HTA requirements.

The remit extends beyond the JCA itself. You will work closely with Market Access, Medical Affairs, Clinical Development and Biostatistics to shape the broader evidence and value strategy for the asset. The focus is on oversight, alignment and strategic direction rather than detailed hands on modelling.

Key areas of responsibility

• Lead preparation and assembly of the JCA dossier, managing timelines, governance and cross functional input

• Oversee vendor led evidence synthesis and statistical workstreams

• Guide targeted and systematic literature reviews, PICO strategy, and payer advisory preparation

• Supervise development of Statistical Analysis Plans and indirect treatment comparisons

• Oversee feasibility assessments for RWE initiatives

• Provide direction on early stage cost effectiveness modelling

• Act as the central HEOR point of contact within ex US cross functional teams

This is a coordination heavy role. The technical work will largely sit with vendors, but strong subject matter expertise is essential to challenge, steer and ensure quality.

Experience required

• Solid oncology background, ideally within rare or targeted oncology

• Direct experience leading JCA or major EU HTA submissions

• Strong understanding of the evolving EU HTA framework

• Experience managing external HEOR vendors

• Comfortable operating in a lean environment where processes are still being established

Experience in melanoma or T cell receptor based therapies would be a plus, but is not essential.

The organisation is expanding its oncology footprint and the HEOR function is in a growth phase, which means visibility is high and impact is tangible. This assignment would suit someone who can bring structure, credibility and strategic clarity at pace.